Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-, pro- or synbiotics) for improving the efficacy of a cancer treatment
View Patent ↗The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
1. A method of treating cancer in a human subject in need thereof, comprising administering to the subject: (a) a probiotic composition comprising an amount of an Enterococcus hirae strain; and (b) dose(s) of an alkylating chemotherapeutic agent, wherein the administering of the probiotic composition and the alkylating chemotherapeutic agent to the subject induces a T-bet/Th1 local and systemic immune response, thereby treating the cancer in the subject.
2. The method of claim 1 , wherein the probiotic composition further comprises at least one additional bacteria selected from the group consisting of Porphyromonas, Barnesiella and Holdemania.
3. The method of claim 2 , wherein the probiotic composition further comprises Lactobacillus johnsonii.
4. The method of claim 1 , wherein the probiotic composition is formulated for oral administration.
5. The method of claim 1 , wherein the probiotic composition is administered to the subject after administration the administering of the alkylating chemotherapeutic agent.
6. The method of claim 1 , wherein the subject has a dysbiosis with an under-representation of bacteria species, and wherein the bacteria species is present in the probiotic composition.
7. The method of claim 1 , wherein the probiotic composition is administered to the subject after administration of a broad-spectrum antibiotic.
8. The method of claim 1 , wherein the Enterococcus hirae strain is Enterococcus hirae strain 13144 Villejuif deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), under the number I-4815, on Nov. 7, 2013.
9. The method of claim 1 , wherein the alkylating chemotherapeutic agent is cyclophosphamide (CTX).
10. The method of claim 1 , wherein the alkylating chemotherapeutic agent is oxaliplatin.
11. A method of treating cancer in a human subject in need thereof, comprising administering to the subject: (a) a probiotic composition comprising an Enterococcus hirae strain; and (b) an alkylating chemotherapeutic agent, to thereby treat the cancer; wherein said Enterococcus hirae strain is one which mediates a TH1 and a pTH17 response in the spleen of C57BL/6 mice treated with broad-spectrum antibiotics for a period of 15 days, followed by administration of said alkylating chemotherapeutic agent in combination with oral gavage delivering 10 9 bacteria from of said Enterococcus hirae strain.
12. The method of claim 11 , wherein the probiotic composition further comprises at least one additional bacteria selected from the group consisting of Porphyromonas, Barnesiella and Holdemania.
13. The method of claim 12 , wherein the probiotic composition further comprises Lactobacillus johnsonii.
14. The method of claim 11 , wherein the probiotic composition is formulated for oral administration.
15. The method of claim 11 , wherein the probiotic composition is administered to the subject after the administering of the alkylating chemotherapeutic agent.
16. The method of claim 11 , wherein the subject has a dysbiosis with an under-representation of bacteria species, and wherein the bacteria species is present in the probiotic composition.
17. The method of claim 11 , wherein the probiotic composition is administered to the subject after administration of a broad-spectrum antibiotic.
18. The method of claim 11 , wherein the Enterococcus hirae strain is Enterococcus hirae strain 13144 Villejuif deposited at the Collection Nationale de Cultures de Microorganismes (CNCM), under the number I-4815, on Nov. 7, 2013.
19. The method of claim 11 , wherein the alkylating chemotherapeutic agent is cyclophosphamide (CTX).
20. The method of claim 11 , wherein the alkylating chemotherapeutic agent is oxaliplatin.